1. Treatment Advances for RA

3. Program Overview

4. Introduction

5. The Unmet Need in RA

6. RA: Burden of Illness

7. RA: Overarching Principles of Therapy

8. Evolution of Treatment Concerns for Patients With RA

9. Residual Symptoms and Disease Burden in Patients With RA in Remission or LDA

10. Pathways of Persistent Pain in RA

11. Cytokines, Growth Factors, and Signaling Pathways Involved in RA Pathogenesis

12. The Biological Significance of Signaling Through Different JAK Combinations

13. JAK Inhibitors in RA

14. ACR20 Responses at Primary Endpoints in Tofacitinib and Baracitinib RCTs

15. RA-BEAM Phase 3: ACR Outcomes at Weeks 12 and 24

16. Tofacitinib Monotherapy, Tofacitinib + MTX, and ADA + MTX in Patients With RA: ORAL Strategy

17. Safety and Efficacy of Tofacitinib for Up to 9
Safety and Efficacy of Tofacitinib for Up to 9.5 Years in the Treatment of RA

18. Safety Profile of Baricitinib for the Treatment of RA Up to 7 Years: Updated Safety Analysis

19. RA Is Associated With an Increased Risk of VTE vs Healthy Controls

20. Increased Risk of PE and Death With Higher Dose of Tofacitinib for RA

21. Risk of Herpes Zoster and JAK Inhibitors

22. Risk of VTE and JAK Inhibitors

23. Oral Strategy: ACR Response Rate at Month 6

24. Baricitinib Monotherapy vs Methotrexate and Baricitinib + Methotrexate: RA-BEGIN

25. JAK Inhibitor Monotherapy vs Combination Therapy With MTX?

26. Considerations for the Use of JAK Inhibitors in Clinical Practice

27. EULAR Recommendations for RA Management

28. Incorporating JAK Inhibitors Into Clinical Practice

29. How Should Patients With Residual Symptoms and Disease Burden Be Managed?

30. Defining Refractory RA

31. Baricitinib vs Placebo or Adalimumab in RA: Results From RA-BEAM

32. Clinical Outcomes In Patients Switched From Adalimumab to Baricitinib: Data From RA-BEAM

33. Importance of the Multidisciplinary Treatment of Patients With RA

34. NICE Recommendations Regarding a Multidisciplinary Approach

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)